Sanofi-Aventis Study Sees Significant A1c Reductions with Lantus and Apidra Compared to Pre-mixed Insulin for Type 2s

5925

At the recent 44th annual meeting of the European Association for the Study of Diabetes (EASD), sanofi-aventis announced a study demonstrating that a basal-bolus insulin regimen with Lantus® once daily (basal insulin) and rapid-acting Apidra® (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) resulted in significant A1c reductions from baseline as compared to pre-mixed insulin in people with type 2 diabetes.

In the GINGER study, the overall A1c change from baseline to endpoint with Lantus and Apidra was 1.3% versus 0.8% with pre-mix.  The number of patients who reached an A1c of less than 7.0% at endpoint was significantly higher with Lantus and Apidra when compared to pre-mixed insulin.

Source: Sanofi-aventis

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.